keyword
MENU ▼
Read by QxMD icon Read
search

ketamine depression

keyword
https://www.readbyqxmd.com/read/28828210/short-and-long-term-antidepressant-effects-of-ketamine-in-a-rat-chronic-unpredictable-stress-model
#1
Yinghong Jiang, Yiqiang Wang, Xiaoran Sun, Bo Lian, Hongwei Sun, Gang Wang, Zhongde Du, Qi Li, Lin Sun
OBJECTIVE: This research was aimed to evaluate the behaviors of short- or long-term antidepressant effects of ketamine in rats exposed to chronic unpredictable stress (CUS). BACKGROUND: Ketamine, a glutamate noncompetitive NMDA receptor antagonist, regulates excitatory amino acid functions, such as anxiety disorders and major depression, and plays an important role in synaptic plasticity and learning and memory. METHODS: After 42 days of CUS model, male rats received either a single injection of ketamine (10 mg/kg; day 43) or 15 daily injections (days 43-75)...
August 2017: Brain and Behavior
https://www.readbyqxmd.com/read/28810160/differences-in-prevalence-socio-behavioral-correlates-and-psychosocial-distress-between-club-drug-and-hard-drug-use-in-taiwan-results-from-the-2014-national-survey-of-substance-use
#2
Wei J Chen, Shang-Chi Wu, Wen-Ing Tsay, Yen-Tyng Chen, Po-Chang Hsiao, Ya-Hui Yu, Te-Tien Ting, Chuan-Yu Chen, Yu-Kang Tu, Jiun-Hau Huang, Hao-Jan Yang, Chung-Yi Li, Carol Strong, Cheng-Fang Yen, Chia-Feng Yen, Jui Hsu
BACKGROUND: This study examined variation between users of 'club' and 'hard' drugs in Taiwan in terms of prevalence of use and demographics and psychosocial characteristics. METHODS: Data were derived from a survey of 17,837 Taiwanese civilians, aged 12-64 years, using stratified, multi-stage, random sampling. Participants completed a computer-assisted self-interview on tablet computers which covered use of legal substances, sedatives/hypnotics and prescription analgesics; use of illicit drugs/inhalants, risky sexual experiences; expectations of drugs; and psychological distress...
August 12, 2017: International Journal on Drug Policy
https://www.readbyqxmd.com/read/28798343/isoflurane-produces-antidepressant-effects-and-induces-trkb-signaling-in-rodents
#3
Hanna Antila, Maria Ryazantseva, Dina Popova, Pia Sipilä, Ramon Guirado, Samuel Kohtala, Ipek Yalcin, Jesse Lindholm, Liisa Vesa, Vinicius Sato, Joshua Cordeira, Henri Autio, Mikhail Kislin, Maribel Rios, Sâmia Joca, Plinio Casarotto, Leonard Khiroug, Sari Lauri, Tomi Taira, Eero Castrén, Tomi Rantamäki
A brief burst-suppressing isoflurane anesthesia has been shown to rapidly alleviate symptoms of depression in a subset of patients, but the neurobiological basis of these observations remains obscure. We show that a single isoflurane anesthesia produces antidepressant-like behavioural effects in the learned helplessness paradigm and regulates molecular events implicated in the mechanism of action of rapid-acting antidepressant ketamine: activation of brain-derived neurotrophic factor (BDNF) receptor TrkB, facilitation of mammalian target of rapamycin (mTOR) signaling pathway and inhibition of glycogen synthase kinase 3β (GSK3β)...
August 10, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28790825/rapid-infusion-of-esketamine-for-unipolar-and-bipolar-depression-a-retrospective-chart-review
#4
Fernanda S Correia-Melo, Felipe C Argolo, Lucas Araújo-de-Freitas, Gustavo Carneiro Leal, Flávio Kapczinski, Acioly Luiz Lacerda, Lucas C Quarantini
BACKGROUND: This study evaluated efficacy and safety of intravenous subanesthetic doses of esketamine using an administration time of 10 minutes in patients with treatment-resistant depression and bipolar depression. METHODS: A retrospective chart review was conducted to identify patients who met the inclusion criteria for treatment-resistant depression and bipolar depression according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision criteria, and these patients received rapid infusion of esketamine between June 2012 and December 2015...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/28781004/ketamine-and-sleep-bridging-the-gap-in-the-treatment-of-depressive-illness
#5
Peter T Morgan
No abstract text is available yet for this article.
September 1, 2017: Biological Psychiatry
https://www.readbyqxmd.com/read/28769008/ketamine-alleviates-depressive-like-behaviors-via-down-regulating-inflammatory-cytokines-induced-by-chronic-restraint-stress-in-mice
#6
Sijie Tan, Yan Wang, Ke Chen, Zhifeng Long, Ju Zou
The purpose of the present study was to investigate whether ketamine's rapid antidepressant effects were associated with its anti-inflammatory actions and to explore the underlying molecular mechanism. Depressive-like behaviors was induced in mice using chronic restraint stress (CRS) method. Anti-depressive effects of ketamine were evaluated by forced swimming tests (FST) and sucrose preference test (SPT). Subsequently, brain tissue was harvested to investigate inflammatory response in the hippocampus via investigating reactive microglia numbers, serum cytokines levels and the toll-like receptor type 4 (TLR4)/p38 mitogen-activated protein kinase (MAPK) pathway...
2017: Biological & Pharmaceutical Bulletin
https://www.readbyqxmd.com/read/28758582/potential-novel-treatments-for-bipolar-depression-ketamine-fatty-acids-anti-inflammatory-agents-and-probiotics
#7
G H Vázquez, S Camino, L Tondo, Ross J Baldessarini
BACKGROUND: Treatments for depression in bipolar disorder (BD) are far less well developed than for unipolar major depressive disorder. Several innovative and experimental approaches have been emerging recently, including use of the dissociative anesthetic ketamine and other antagonists of central NMDA glutamate receptors, as well as unsaturated fatty acids, anti-inflammatory agents, and possibly probiotic methods. METHODS: We reviewed relevant reports from the past decade...
July 28, 2017: CNS & Neurological Disorders Drug Targets
https://www.readbyqxmd.com/read/28757132/side-effects-associated-with-ketamine-use-in-depression-a-systematic-review
#8
REVIEW
Brooke Short, Joanna Fong, Veronica Galvez, William Shelker, Colleen K Loo
This is the first systematic review of the safety of ketamine in the treatment of depression after single and repeated doses. We searched MEDLINE, PubMed, PsycINFO, and Cochrane Databases and identified 288 articles, 60 of which met the inclusion criteria. After acute dosing, psychiatric, psychotomimetic, cardiovascular, neurological, and other side-effects were more frequently reported after ketamine treatment than after placebo in patients with depresssion. Our findings suggest a selective reporting bias with limited assessment of long-term use and safety and after repeated dosing, despite these being reported in other patient groups exposed to ketamine (eg, those with chronic pain) and in recreational users...
July 27, 2017: Lancet Psychiatry
https://www.readbyqxmd.com/read/28756462/effects-of-gaba-b-receptor-positive-modulator-on-ketamine-induced-psychosis-relevant-behaviors-and-hippocampal-electrical-activity-in-freely-moving-rats
#9
Jingyi Ma, L Stan Leung
RATIONALE: Decreased GABAB receptor function is proposed to mediate some symptoms of schizophrenia. OBJECTIVES: In this study, we tested the effect of CGP7930, a GABAB receptor positive allosteric modulator, on ketamine-induced psychosis-relevant behaviors and hippocampal electrical activity in behaving rats. METHODS: Electrodes were bilaterally implanted into the hippocampus, and cannulae were placed into the lateral ventricles of Long-Evans rats...
July 29, 2017: Psychopharmacology
https://www.readbyqxmd.com/read/28754288/involvement-of-nmda-receptors-in-the-antidepressant-like-effect-of-tramadol-in-the-mouse-forced-swimming-test
#10
Sattar Ostadhadi, Abbas Norouzi-Javidan, Mohsen Chamanara, Reyhaneh Akbarian, Muhammad Imran-Khan, Mehdi Ghasemi, Ahmad-Reza Dehpour
Tramadol is an analgesic agent that is mainly used to treat moderate to severe pain. There is evidence that tramadol may have antidepressant property. However, the mechanisms underlying the antidepressant effects of tramadol have not been elucidated yet. Considering that fact that N-methyl-d-aspartate (NMDA) receptor signaling may play an important role in the pathophysiology of depression, the aim of the present study was to investigate the role of NMDA receptor signaling in the possible antidepressant-like effects of tramadol in the mouse forced swimming test (mFST)...
July 25, 2017: Brain Research Bulletin
https://www.readbyqxmd.com/read/28749092/ketamine-for-depression-4-in-what-dose-at-what-rate-by-what-route-for-how-long-and-at-what-frequency
#11
Chittaranjan Andrade
BACKGROUND: Ketamine, administered in subanesthetic doses, is an effective off-label treatment for severe and even treatment-refractory depression; however, despite dozens of studies across nearly 2 decades of research, there is no definitive guidance on matters related to core practice issues. METHODS: This article presents a qualitative review and summary about what is known about ketamine dosing, rate of administration, route of administration, duration of treatment, and frequency of sessions...
July 25, 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28748374/alterations-in-amino-acid-levels-in-mouse-brain-regions-after-adjunctive-treatment-of-brexpiprazole-with-fluoxetine-comparison-with-r-ketamine
#12
Min Ma, Qian Ren, Yuko Fujita, Chun Yang, Chao Dong, Yuta Ohgi, Takashi Futamura, Kenji Hashimoto
RATIONALE: Brexpiprazole, a serotonin-dopamine activity modulator, is approved in the USA as an adjunctive therapy to antidepressants for treating major depressive disorders. Similar to the N-methyl-D-aspartate receptor (NMDAR) antagonist ketamine, the combination of brexpiprazole and fluoxetine has demonstrated antidepressant-like effects in animal models of depression. OBJECTIVES: The present study was conducted to examine whether the combination of brexpiprazole and fluoxetine could affect the tissue levels of amino acids [glutamate, glutamine, γ-aminobutyric acid (GABA), D-serine, L-serine, and glycine] that are associated with NMDAR neurotransmission...
July 26, 2017: Psychopharmacology
https://www.readbyqxmd.com/read/28739263/pilot-randomized-controlled-trial-of-titrated-subcutaneous-ketamine-in-older-patients-with-treatment-resistant-depression
#13
Duncan George, Verònica Gálvez, Donel Martin, Divya Kumar, John Leyden, Dusan Hadzi-Pavlovic, Simon Harper, Henry Brodaty, Paul Glue, Rohan Taylor, Philip B Mitchell, Colleen K Loo
OBJECTIVE: To assess the efficacy and safety of subcutaneous ketamine for geriatric treatment-resistant depression. Secondary aims were to examine if repeated treatments were safe and more effective in inducing or prolonging remission than a single treatment. METHODS: In this double-blind, controlled, multiple-crossover study with a 6-month follow-up (randomized controlled trial [RCT] phase), 16 participants (≥60 years) with treatment-resistant depression who relapsed after remission or did not remit in the RCT were administered an open-label phase...
June 13, 2017: American Journal of Geriatric Psychiatry
https://www.readbyqxmd.com/read/28731926/history-of-anaesthesia-the-ketamine-story-past-present-and-future
#14
Georges Mion
No abstract text is available yet for this article.
September 2017: European Journal of Anaesthesiology
https://www.readbyqxmd.com/read/28707385/risk-factors-of-lower-urinary-tract-syndrome-among-ketamine-users
#15
I-Chun Chen, Ming-Huei Lee, Wei-Chih Chen, Tsung-Ching Hu, Hsiu-Ying Lin
OBJECTIVE: This study investigated the risk factors of ketamine associated-lower urinary tract symptoms (LUTS), such as duration of use, dosage of ketamine, co-occurring substance use of other psychoactive drugs, comorbidities, and depression. METHODS: This study was a cross-sectional survey. LUTS was assessed with the O'Leary symptom and problem index (OSPI) scores. We included the comorbidities of interstitial cystitis/painful bladder syndrome (IC/PBS) as comorbid factors...
July 13, 2017: Lower Urinary Tract Symptoms
https://www.readbyqxmd.com/read/28704275/agonist-e-6837-and-antagonist-sb-271046-of-5-ht6-receptors-both-reverse-the-depressive-like-effect-induced-in-mice-by-subchronic-ketamine-administration
#16
José E Suárez-Santiago, Alfredo Briones-Aranda, Judith Espinosa-Raya, Ofir Picazo
Major depression is one of the most common affective disorders caused by schizophrenia. The administration of N-methyl-D-aspartate receptor antagonists, such as ketamine, can reproduce the negative and affective symptoms of this disorder in animals. Preclinical studies have shown that 5-HT6 receptor (5-HT6R) agonists and antagonists have a considerable antipsychotic response. The aim of the present study was to evaluate the effect of an acute treatment with an agonist, E-6837, and an antagonist, SB-271046, of 5-HT6R on the immobility induced in mice by a subchronic ketamine regimen (5 days; 10 mg/kg/day, intraperitoneal)...
July 12, 2017: Behavioural Pharmacology
https://www.readbyqxmd.com/read/28702841/comparison-of-ketamine-and-ketofol-for-deep-sedation-and-analgesia-in-children-undergoing-laser-procedure
#17
Marija Stevic, Nina Ristic, Ivana Budic, Nebojsa Ladjevic, Branislav Trifunovic, Ivan Rakic, Marko Majstorovic, Ivana Burazor, Dusica Simic
The aim of our study was to research and evaluate cardiovascular and respiratory stability, clinical efficacy, and safety of two different anesthetic agents in pediatric patients who underwent Pulse dye (wavelength 595 nm, pulse duration 0-40 ms, power 0-40 J) and CO2 (wavelength 10,600 nm, intensity-fraxel mod with SX index 4 to 8, power 0-30 W) laser procedure. This prospective non-blinded study included 203 pediatric patients ASA I-II, aged between 1 month and 12 years who underwent short-term procedural sedation and analgesia for the laser procedure...
July 12, 2017: Lasers in Medical Science
https://www.readbyqxmd.com/read/28700802/ketamine-for-the-treatment-of-depression
#18
Christoph Kraus, Rupert Lanzenberger, Siegfried Kasper
No abstract text is available yet for this article.
July 12, 2017: JAMA Psychiatry
https://www.readbyqxmd.com/read/28700782/ketamine-for-the-treatment-of-depression
#19
Keith G Rasmussen
No abstract text is available yet for this article.
July 12, 2017: JAMA Psychiatry
https://www.readbyqxmd.com/read/28700777/ketamine-for-the-treatment-of-depression
#20
Samad E J Golzari, Ata Mahmoodpoor
No abstract text is available yet for this article.
July 12, 2017: JAMA Psychiatry
keyword
keyword
28799
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"